Past novel anti-cancer drugs containing the platinum (Pt) metal as the central atom have been clinically recognized as being unsuccessful in cancer treatment. These platinum based drugs are administered during chemotherapy treatment to cancer patients. The �down fall� of these chemotherapy drugs is that they destroy the surrounding normal cells (tissue) during the treatment process. This is attributed to platinum based drugs being insoluble. Ruthenium complexes offer the potential of reduced toxicity, a novel mechanism of action, non-cross resistance and a different spectrum of activity compared to platinum containing compounds. Ruthenium organometallic complexes form monofunctional adducts with guanine in DNA in vitro and have a cytotoxic anticancer activity spectrum in preclinical models that suggests a lack of cross-resistance with the platinum based pharmaceutical drug, Cisplatin. The synthesis of Diruthenium with Allopurinol (ALP) and its activity toward the Mammalian cancer cell line (MCF-7) and Basal Epithelial cell line was presented in past cancer research findings. Research efforts were successful in the synthesis and characterization of the Diruthenium-Allopurinol (Ruthanol) complex using the UV-Visible in which spectral graphs yielded identifying peaks at 291, 301, and 642 nm(s). Identifying peaks from the FT-IR were at 1698 nm and 1699 nm. The mass of the compound was identified and determined as 665 (m/z) using the Bruker Microflex Daltonics TOF-MALDI instrument. The cytotoxicity level in the MCF-7 cell line at 104 was 73% at 75 mM; whereas the percent viability in the Basal Epithelial Cell line was 80%. MCF-7 cells are non-invasive and the tumors remain where they originate, the MDA-MB231 cells are selected for the current study. The MDA-MB 231 cells are highly invasive and they are capable of metastasizing throughout the body. Preliminary cell culturing of the MDA-MB 231 cell line, administration of the above mentioned drug complex and Neutral Red Assay analysis in the current screening study provides experimental evidence to classify �Ruthanol� as an anti-metastatic drug

In vitro assessment on the effect of diruthenium- allopurinol as a potential anticancer agent in Michigan cancer foundation -7 (MCF-7) breast cancer cells

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.